Paediatric sleep apnoea: snoring, adenotonsillectomy and the AU GP approach

Snoring that goes beyond snoring

Most children snore occasionally. What raises a clinical flag is habitual loud snoring — present most nights, audible from outside the bedroom, and accompanied by the characteristic features of upper-airway obstruction during sleep: restless sleep, unusual sleeping positions (neck hyperextended, propped upright, prone with the head elevated), gasping or snorting arousals, and pauses in breathing witnessed by parents.

Paediatric obstructive sleep apnoea (OSA) sits on a continuum from primary snoring through to complete upper-airway obstruction during sleep. An abnormal threshold in children is defined as an apnoea–hypopnoea index (AHI) ≥ 1 event per hour — far lower than the adult threshold of ≥ 5 per hour — reflecting the greater vulnerability of the developing nervous system and cardiovascular system to even mild nocturnal hypoxaemia. The Australasian Sleep Association and the AAP Clinical Practice Guideline (2012) both use this paediatric-specific threshold.

Prevalence is approximately 1–4% of Australian children, with habitual snoring affecting around 10% (most of whom do not have OSA). The condition peaks between ages 2 and 8 years, when adenotonsillar hypertrophy is greatest relative to airway calibre. As the childhood obesity epidemic grows, adolescent-pattern OSA — resembling the adult form with sleepiness and metabolic consequences — is becoming increasingly common.

The key clinical insight for general practice: children with OSA are much less likely than adults to report feeling sleepy during the day. Instead, they present with hyperactivity, inattention, irritability, and oppositional behaviour — a pattern frequently misattributed to attention deficit hyperactivity disorder (ADHD). Treating the underlying sleep disorder can resolve the behavioural picture entirely. This is why sleep screening belongs in the workup of any child before a stimulant trial is considered.

Severity bands, per the AAP guideline: mild AHI 1–4 per hour, moderate 5–9, severe ≥ 10 per hour.

A. Core clinical — the AU general-practice framework

Risk factors

The most common risk factor in young children is adenotonsillar hypertrophy — the single biggest contributor in the 2–8-year age group. Other important risk factors include:

• Childhood obesity — increasingly dominant in adolescents, who present with adult-pattern OSA
• Craniofacial anomalies — Pierre Robin sequence, Treacher Collins syndrome, Apert and Crouzon syndromes, mid-face hypoplasia, retrognathia
• Down syndrome (trisomy 21) — prevalence approximately 80% due to mid-face hypoplasia, macroglossia, hypotonia, and glossoptosis; the AAP recommends universal PSG screening by age 4 years regardless of symptoms
• Neuromuscular disease — Duchenne muscular dystrophy, spinal muscular atrophy, cerebral palsy
• Allergic rhinitis and chronic nasal obstruction — contributes to nasal resistance and mouth breathing
• Prematurity, parental smoking (including household exposure), and family history of OSA
• First Nations children — higher prevalence with significant under-detection; integrate sleep screening into every 715 health check

What to look for in history

Ask about both nocturnal and daytime symptoms. A brief smartphone video recording of the child snoring, made by the parent, is one of the most useful clinical tools in general practice — it demonstrates severity, sleeping position, and whether there are witnessed apnoeic episodes.

Nocturnal symptoms:

• Habitual loud snoring, every night, audible outside the room
• Witnessed pauses in breathing, gasping, snorting, or choking arousals
• Restless sleep with frequent position changes
• Neck hyperextension or unusual sleeping positions
• Sweating, particularly of the head and neck
• Secondary nocturnal enuresis (resuming after a dry period)
• Mouth breathing audible at rest

Daytime symptoms (the key paediatric–adult difference):

• Hyperactivity, impulsivity, inattention — the cardinal paediatric daytime presentation
• Irritability, mood lability, oppositional behaviour
• Poor academic performance; teacher reports of inattention
• Morning headache, dry mouth
• Daytime tiredness — less prominent in children than adults; more evident in obese adolescents

Examination

• Tonsil grading (Brodsky scale 0–4+): Grades 3+ (past the pillars) and 4+ (kissing tonsils at midline) are strongly associated with OSA in young children
• Adenoid facies: long open-mouth face, high-arched palate, dental crowding, dark infraorbital circles, retrognathia
• Mouth breathing at rest in the clinic
• Nasal patency: deviated septum, turbinate hypertrophy (nasal polyps are uncommon in children)
• BMI and growth chart — growth retardation occurs in severe OSA and reverses with treatment
• Blood pressure — elevated in significant untreated OSA, often overlooked in children

Investigations in general practice

For most healthy children aged 2–8 years with a classic presentation and large tonsils, clinical assessment guides referral directly without investigations. Where workup is needed:

• Overnight pulse oximetry — useful general practice screen where access to polysomnography is limited; a positive result (clusters of desaturation events) confirms OSA, but a negative result does not exclude it
• Polysomnography (PSG) — gold standard; access in Australia is largely through tertiary paediatric centres (Royal Children’s Hospital Melbourne, Sydney Children’s Hospital, Westmead, Queensland Children’s Hospital, Perth Children’s Hospital, Women’s and Children’s Adelaide); indicated for complex, atypical, or severe presentations, comorbidities, or pre-operative planning in high-risk children
• Lateral neck X-ray — adenoid size assessment when nasendoscopy is unavailable; less commonly used now
• Echocardiogram — if pulmonary hypertension is suspected in severe untreated OSA or Down syndrome with moderate-to-severe AHI

B. Evidence for adenotonsillectomy — the CHAT trial and its limits

The pivotal evidence for surgical intervention comes from the Childhood Adenotonsillectomy Trial (CHAT) — a randomised controlled trial published in the NEJM (Marcus et al. 2013) involving 464 children aged 5–9 years with mild-to-moderate OSA (AHI 2–30 per hour). The trial compared early adenotonsillectomy with seven months of watchful waiting:

• Early adenotonsillectomy was significantly superior for behavioural outcomes, quality of life, symptom scores, and polysomnographic normalisation
• PSG normalisation rates: 79% with early surgery versus 46% with watchful waiting
• The primary neuropsychological endpoint (NEPSY attention subscale) was not significantly different — an important nuance
• Approximately 46% of the watchful-waiting group improved spontaneously over seven months

What the CHAT trial means for practice: early adenotonsillectomy is favoured for children with significant behavioural, quality-of-life, and sleep-study burden. Watchful waiting is a reasonable option for selected children with mild symptoms and engaged, informed parents who understand the monitoring plan and red flags.

The RCH Melbourne Clinical Practice Guideline and AAP guideline (2012) are concordant: adenotonsillectomy is first-line for paediatric OSA in children with adenotonsillar hypertrophy.

Evidence for non-surgical adjuncts

• Intranasal corticosteroids (fluticasone, mometasone) — reduce adenoid size and AHI modestly in mild OSA with coexisting allergic rhinitis; reasonable while awaiting ENT referral or as sole treatment for mild cases
• CPAP (continuous positive airway pressure) — first-line for children who cannot have surgery, have failed surgery, or have craniofacial or neuromuscular conditions preventing adequate surgical benefit; mask fitting and adherence in children requires specialist support from paediatric respiratory or sleep services
• Weight management — in obese adolescents, OSA resolution with adenotonsillectomy drops to approximately 50%; weight management is the central therapeutic lever, with CPAP often required in addition
• Rapid maxillary expansion (orthodontic) — for children with narrow, high-arched palate and mild OSA; coordinates with a paediatric orthodontist; not a substitute for adenotonsillectomy where adenotonsillar hypertrophy is the primary driver

What to avoid

Montelukast was previously used for mild paediatric OSA with adenoidal hypertrophy. Following the TGA boxed warning (March 2020) for neuropsychiatric events — including sleep disturbances, aggression, depression, and suicidality — it is no longer appropriate as first-line treatment for OSA. Reserve only for severe allergic asthma where clinically indicated, with documented informed consent about neuropsychiatric risk.

Codeine is contraindicated in children under 12 years and in all children after adenotonsillectomy for OSA. The TGA issued a safety alert (2013, updated 2018) following deaths in children who were CYP2D6 ultra-rapid metabolisers and converted codeine to morphine at toxic rates. Standard post-operative analgesia is paracetamol and ibuprofen as directed by the operating surgeon.

C. Post-operative care and safety-netting

Most ENT surgeons in Australia discharge healthy children after adenotonsillectomy the same day, provided discharge criteria are met. The AAP guideline (2012) recommends overnight hospital observation for:

• AHI greater than 10 events per hour
• Age under 3 years
• Down syndrome, craniofacial anomalies, or neuromuscular disease
• Obesity with cardiopulmonary comorbidities
• Signs of cardiovascular compromise pre-operatively

Post-tonsillectomy haemorrhage — the critical safety message

Post-operative bleeding is the most important risk to counsel families about. It occurs in approximately 1–5% of children and has two peaks:

• Primary haemorrhage — within 24 hours of surgery; managed in hospital
• Secondary haemorrhage — typically days 5–10 when the post-operative eschar separates; presents as sudden fresh bright red bleeding from the mouth, often at night when the family has been reassured everything is healing

Any post-tonsillectomy bleeding requires immediate presentation to an emergency department. GPs who see a child with post-tonsillectomy bleeding should facilitate urgent ED transfer — do not attempt local haemostasis in the community. Give families this instruction explicitly at discharge: even what appears to be a small amount of bleeding warrants emergency review, because haemorrhage can escalate rapidly.

Follow-up after adenotonsillectomy

• ENT review at 2–6 weeks post-operatively
• GP review at 3–6 months — assess resolution of snoring, behavioural symptoms, and plot growth
• Repeat polysomnography only if symptoms persist or worsen — OSA persists in approximately 20–40% of obese children and a smaller proportion of non-obese children even after technically successful surgery

D. Australian operations

Referral pathway

1. Identify habitual snoring + OSA features on history and examination — tonsil grade, adenoid facies, growth, BMI, behavioural and academic impact
2. Mild symptoms, no red flags, child over 3 years: trial of intranasal corticosteroid for 6–8 weeks if allergic rhinitis coexists; sleep hygiene; watchful waiting with a clear review date and documented safety-netting
3. Moderate-to-severe symptoms / any red flag / failed conservative management: referral to ENT for clinical assessment, nasendoscopy, and adenotonsillectomy planning
4. Complex cases — Down syndrome, craniofacial anomalies, neuromuscular disease, age under 2, obesity with comorbidities: paediatric sleep medicine plus PSG at a tertiary paediatric centre before planning surgery
5. Post-surgical follow-up: ENT at 2–6 weeks; GP at 3–6 months; re-refer if symptoms persist

MBS items relevant to general practice

(Verify current descriptors at MBS Online — item numbers change.)

• Standard GP consultations: items 23, 36, 44
• First Nations Health Assessment: item 715 — integrate structured sleep screening for Aboriginal and Torres Strait Islander children
• GP Management Plan / Team Care Arrangement: items 721/723 where OSA contributes to chronic complex presentations (e.g. with childhood obesity, behavioural comorbidity)
• Allied health under chronic disease management (dietetics for obesity, speech pathology or myofunctional therapy): item 10970
• Paediatric polysomnography — typically referred via paediatrician or sleep physician; verify current item numbers at MBS Online
• Telehealth items 91790/92029 for follow-up where appropriate

PBS medications

• Fluticasone nasal spray — PBS general benefit; verify minimum age threshold
• Mometasone nasal spray — PBS Authority for paediatric allergic rhinitis; verify age eligibility
• Montelukast — not for isolated OSA (TGA boxed warning 2020); PBS streamlined for asthma only
• Paracetamol and ibuprofen — standard post-operative analgesia; codeine contraindicated under 12 years and after tonsillectomy for OSA

E. Special populations

Down syndrome (trisomy 21). The AAP recommends universal PSG screening by age 4 years regardless of symptoms, given the approximately 80% prevalence and the fact that many children with Down syndrome cannot reliably report symptoms. Adenotonsillectomy resolves OSA in only approximately 50% — lower than the general paediatric population — due to multilevel airway obstruction from macroglossia, glossoptosis, and mid-face hypoplasia. CPAP and, increasingly, hypoglossal nerve stimulation are frequently required. Multi-disciplinary co-management with paediatrics and sleep medicine is standard.

Aboriginal and Torres Strait Islander children. Higher prevalence of paediatric OSA with significant under-detection. Integrate structured sleep questioning into every 715 Health Check. Apply a lower referral threshold. Address modifiable environmental risk factors including household smoking and overcrowding. Culturally safe referral pathways are important — telehealth ENT and sleep services are expanding into regional and remote areas through the Australasian Sleep Association network.

Obese adolescents. OSA in this group resembles adult-pattern disease — daytime sleepiness, metabolic consequences, and a substantially lower rate of resolution with adenotonsillectomy (approximately 50% versus 60–80% in non-obese younger children). Weight management is the central therapeutic goal. CPAP is often required in addition to or instead of surgery. The Thoracic Society of Australia & New Zealand and Australasian Sleep Association publish current position statements for this group.

Rural and regional families. Paediatric PSG access is limited outside tertiary paediatric centres in capital cities. Overnight pulse oximetry is an appropriate and pragmatic screening tool that can be arranged in most regional centres. Telehealth ENT and paediatric sleep consultations are increasingly available through state-based services — the Sleep Health Foundation maintains a practitioner directory.

Neuromuscular disease. Children with Duchenne muscular dystrophy, spinal muscular atrophy, and cerebral palsy have high OSA prevalence driven by pharyngeal hypotonia rather than adenotonsillar hypertrophy. CPAP or bilevel positive airway pressure (BiPAP) is usually the primary treatment; adenotonsillectomy is less effective and carries higher anaesthetic risk. Multi-disciplinary paediatric respiratory review is essential before and after any surgical decision.

When to escalate

Refer urgently or arrange emergency care:

• Post-tonsillectomy bleeding — ED immediately; even apparently minor fresh bleeding requires emergency assessment given the risk of sudden heavy haemorrhage
• Signs of pulmonary hypertension or cor pulmonale — right-sided heart failure from untreated severe OSA is an urgent referral; do not watch and wait
• Cyanotic spells or frank witnessed apnoea during waking hours — emergency assessment
• Failure to thrive with habitual snoring — exclude OSA as a driver of growth faltering

Refer electively to ENT or paediatric sleep medicine:

• Moderate-to-severe OSA features in any child, or any OSA features in a child under 3 years
• Failure to improve with a trial of intranasal corticosteroids and conservative management
• Complex comorbidities: Down syndrome, craniofacial anomalies, neuromuscular disease, morbid obesity
• OSA persisting or recurring after adenotonsillectomy
• Diagnostic uncertainty when pulse oximetry is negative but symptoms continue — a negative oximetry does not exclude OSA

What this article is and is not

This is general health information drawn from current Australian and international paediatric sleep guidelines — Australasian Sleep Association, AAP Clinical Practice Guideline (2012), RCH Melbourne Clinical Practice Guideline, RACGP, Therapeutic Guidelines, Sleep Health Foundation, and the CHAT randomised controlled trial. It is not personal medical advice and does not create a doctor–patient relationship. Treatment decisions — including referral, investigation, and surgical options — are made with your own GP and treating specialists.

For Australian consumer resources: HealthDirect, Sleep Health Foundation, Better Health Channel.

For breathing emergencies or post-operative bleeding: call 000 or present directly to the nearest emergency department.

For acute mental health concerns related to your child’s wellbeing: Lifeline 13 11 14, Beyond Blue 1300 22 4636, Kids Helpline 1800 55 1800, 13YARN 13 92 76 (First Nations).

---

Sources cited

1. Australasian Sleep Association (ASA)
2. Sleep Health Foundation — Children’s sleep
3. RACGP — Paediatric sleep-disordered breathing (AJGP)
4. Therapeutic Guidelines (eTG) — Paediatric / ENT
5. RCH Melbourne CPG — Obstructive sleep apnoea
6. Australian Society of Otolaryngology Head & Neck Surgery (ASOHNS)
7. Thoracic Society of Australia & New Zealand (TSANZ)
8. Marcus CL et al. — AAP Clinical Practice Guideline for Childhood OSAS (AAP 2012)
9. Marcus CL et al. — CHAT trial: adenotonsillectomy for childhood sleep apnoea (NEJM 2013)
10. AAP — Health Supervision for Children with Down Syndrome (AAP 2022)
11. TGA — Montelukast neuropsychiatric events boxed warning (March 2020)
12. TGA — Codeine contraindicated in children under 12 years
13. HealthDirect — Sleep apnoea in children
14. Better Health Channel
15. MBS Online
16. PBS Online